Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines

被引:0
作者
Sara Nannizzi
Gareth J. Veal
Elisa Giovannetti
Valentina Mey
Simona Ricciardi
Christopher J. Ottley
Mario Del Tacca
Romano Danesi
机构
[1] University of Pisa,Division of Pharmacology and Chemotherapy, Department of Internal Medicine
[2] Newcastle University,Northern Institute for Cancer Research, Medical School
[3] VU University Medical Center,Department of Medical Oncology
[4] Durham University,Department of Earth Sciences
来源
Cancer Chemotherapy and Pharmacology | 2010年 / 66卷
关键词
Colon cancer; Oxaliplatin; Pemetrexed; Gene expression; DNA repair; DNA adducts;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:547 / 558
页数:11
相关论文
共 349 条
[1]  
Jemal A(2009)Cancer statistics, 2009 CA Cancer J Clin 59 225-249
[2]  
Siegel R(2005)Advances in the treatment of metastatic colorectal cancer Oncologist 10 40-48
[3]  
Ward E(2005)Systemic therapy for colorectal cancer N Engl J Med 352 476-487
[4]  
Hao Y(2002)Cellular and molecular pharmacology of oxaliplatin Mol Cancer Ther 1 227-235
[5]  
Xu J(2005)Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy Cancer Treat Rev 31 90-105
[6]  
Thun MJ(1999)Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts Cancer Res 59 3968-3971
[7]  
Goldberg RM(2003)Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines Eur J Cancer 39 112-119
[8]  
Meyerhardt JA(2005)Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin Biochem Biophys Res Commun 327 225-233
[9]  
Mayer RJ(2001)ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy J Clin Oncol 19 4298-4304
[10]  
Raymond E(2002)DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program Anticancer Drugs 13 511-519